Subarachnoid haemorrhage (SAH) is the third most common subtype of stroke. Incidence
has decreased over past decades, possibly in part related to lifestyle changes such as …

Importance Tranexamic acid (TXA) is an efficient antifibrinolytic agent; however, concerns
remain about the potential adverse effects, particularly vascular occlusive events, that may …

Background The neurointensive care management of patients with aneurysmal
subarachnoid hemorrhage (aSAH) is one of the most critical components contributing to …

Subarachnoid haemorrhage is an uncommon and severe subtype of stroke affecting
patients at a mean age of 55 years, leading to loss of many years of productive life. The …

Key Clinical Points Subarachnoid Hemorrhage Subarachnoid hemorrhage from a ruptured
intracranial aneurysm is a life-threatening stroke that affects younger patients than those …

Background Tranexamic acid (TXA) reduces surgical bleeding and reduces death from
bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures …

Unruptured intracranial aneurysms (UIAs) are commonly acquired vascular lesions that form
an outpouching of the arterial wall due to wall thinning. The prevalence of UIAs in the …

Background In patients with aneurysmal subarachnoid haemorrhage, short-term
antifibrinolytic therapy with tranexamic acid has been shown to reduce the risk of rebleeding …

Purpose—The aim of this guideline is to present current and comprehensive
recommendations for the diagnosis and treatment of aneurysmal subarachnoid hemorrhage …

Background: Intracranial aneurysm with and without subarachnoid haemorrhage (SAH) is a
relevant health problem: The overall incidence is about 9 per 100,000 with a wide range, in …